Linked Data API

Show Search Form

Search Results

100402
registered interest false more like this
date less than 2014-10-22more like thismore than 2014-10-22
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Paralysis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he has taken to support University College London in its work to enable people who have been paralysed to regain the ability to walk. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 211576 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-27more like thismore than 2014-10-27
answer text <p>The Department’s National Institute for Health Research (NIHR) funds 11 biomedical research centres that conduct translational research to transform scientific breakthroughs into benefits for patients. These centres are formed through partnerships between England’s leading National Health Service organisations and universities.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £110 million over five years (2012-17) in the NIHR biomedical research centre at University College London Hospitals NHS Foundation Trust and University College London. The centre is supporting research on the use of cells from the lining of the nose to repair damaged nerves in the spinal cord.</p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
remove maximum value filtermore like thismore than 2014-10-27T16:53:22.0851128Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4131
label Biography information for Jim Shannon more like this
100411
registered interest false more like this
date less than 2014-10-22more like thismore than 2014-10-22
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Cystic Fibrosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis. more like this
tabling member constituency Barnsley Central more like this
tabling member printed
Dan Jarvis more like this
uin 211584 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-27more like thismore than 2014-10-27
answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-27T16:52:12.8962611Zmore like thismore than 2014-10-27T16:52:12.8962611Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4243
label Biography information for Dan Jarvis more like this
99859
registered interest false more like this
date less than 2014-10-20more like thismore than 2014-10-20
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Prescription Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, if his Department will commission a review of the innovation, evaluation and adoption of new medicines in the NHS; and if he will make a statement. more like this
tabling member constituency Scunthorpe more like this
tabling member printed
Nic Dakin more like this
uin 211101 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-23more like thismore than 2014-10-23
answer text <p>We are committed to ensuring National Health Service patients have access to effective medicines on terms that represent value to the NHS and taxpayers and that patients, are supported to get the best outcomes from their medicines.</p><p> </p><p> </p><p> </p><p>The Department, in collaboration with NHS England, has recently commissioned an independent evaluation of Innovation Health and Wealth. Jointly led by the University of Manchester and RAND Europe, The first initial phase is now underway, the study is expected to take three years to complete.</p><p> </p><p><em> </em></p><p> </p><p>In addition, NHS England, with the Health and Social Care Information Centre publishes an innovation scorecard which represents the rate of uptake and utility of medicines in both primary and secondary care, on a regular basis. This publication sets out levels of uptake and utility for National Institute for Health and Care Excellence appraised medicines and technologies, and evidence suggests that steady growth is being achieved and the most recent information is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/searchcatalogue?productid=15598&amp;q=innovation+scorecard&amp;sort=Relevance&amp;size=10&amp;page=1#top" target="_blank">www.hscic.gov.uk/searchcatalogue?productid=15598&amp;q=innovation+scorecard&amp;sort=Relevance&amp;size=10&amp;page=1#top</a></p><p> </p><p><strong> </strong></p><p> </p><p>Earlier this year, NHS England also undertook an extensive consultation to ‘refresh’ the Innovation Health and Wealth policy framework and we understand that recommendations from this will be included in NHS England's five year Forward Look.</p><p> </p>
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-23T16:35:13.9262134Zmore like thismore than 2014-10-23T16:35:13.9262134Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4056
label Biography information for Nic Dakin more like this
99878
registered interest false more like this
date less than 2014-10-20more like thismore than 2014-10-20
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Hepatitis: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much his Department spent on medicines for hepatitis C treatment in each of the last three financial years. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 211146 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-23more like thismore than 2014-10-23
answer text <p>Information on spend by the National Health Service in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Medicines for the treatment of hepatitis C have been defined as all medicines contained within British National Formulary section 5.3.3.4 - chronic hepatitis C. In addition, peginterferon alfa, ribavirin and interferon alfa have also been included as they have been recommended in National Institute for Health and Care excellence technology appraisals for use in treating hepatitis C.</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed and therefore figures may include costs from prescriptions of these drugs other than for hepatitis C.</p><p> </p><p><strong> </strong></p><p> </p><p>This is the cost of the medicines at NHS list price and not necessarily the price paid. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p> </p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Cost (£000)</p></td></tr><tr><td><p>2011-12</p></td><td><p>34,198.9</p></td></tr><tr><td><p>2012-13</p></td><td><p>52,709.2</p></td></tr><tr><td><p>2013-14</p></td><td><p>72,122.0</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-23T16:40:20.5892873Zmore like thismore than 2014-10-23T16:40:20.5892873Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4036
label Biography information for Luciana Berger more like this
93839
registered interest false more like this
date less than 2014-10-16more like thismore than 2014-10-16
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Mental Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what National Institute for Health and Care Excellence-approved interventions are available through the NHS for the treatment of mental health conditions. more like this
tabling member constituency East Worthing and Shoreham more like this
tabling member printed
Tim Loughton more like this
uin 210896 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-21more like thismore than 2014-10-21
answer text <p>The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia. Clinical guidelines provide guidance on the treatment of patients across the care pathway and each guideline recommends a number of treatments.<br> <br> Additionally, the following technologies for the treatment of mental health and behavioural conditions are recommended by NICE technology appraisal guidance:</p><p> </p><table><tbody><tr><td><p>Appraisal Number</p></td><td><p>Year</p></td><td><p>Technology</p></td><td><p>Condition</p></td><td><p>Categorisation</p></td></tr><tr><td><p>TA59</p></td><td><p>2003</p></td><td><p>Electroconvulsive therapy</p></td><td><p>Catatonia/ prolonged or severe manic episode</p></td><td><p>Optimised<sup>1</sup></p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Atomoxetine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Dexamfetamine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Methylphenidate</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA213</p></td><td><p>2011</p></td><td><p>Aripiprazole</p></td><td><p>Schizophrenia in people aged 15-17 years</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Donepezil</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Galantamine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Rivastigmine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (moderate)</p></td><td><p>Optimised</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (severe)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA292</p></td><td><p>2013</p></td><td><p>Aripiprazole</p></td><td><p>Moderate to severe manic episodes in adolescents with bipolar disorder</p></td><td><p>Recommended</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Source</em>: National Institute for Health and Care Excellence</p><p> </p><p> </p><p> </p><p><sup>1 </sup>The drug or technology is recommended for a smaller subset of patients than originally stated by the marketing authorisation.</p><p> </p><p> </p><p> </p><p>Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate.</p><p> </p><p> </p><p> </p><p>Details of all NICE’s guidance on mental health and behavioural conditions can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions" target="_blank">www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions</a></p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-21T15:12:00.8391961Zmore like thismore than 2014-10-21T15:12:00.8391961Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
114
label Biography information for Tim Loughton more like this
100022
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Patient Choice Schemes more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he is taking to promote patient choice. more like this
tabling member constituency Stroud more like this
tabling member printed
Neil Carmichael more like this
uin 905559 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-21more like thismore than 2014-10-21
answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> more like this
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-21T16:00:56.1397924Zmore like thismore than 2014-10-21T16:00:56.1397924Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4104
label Biography information for Neil Carmichael more like this
93566
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Pharmaceutical Price Regulation Scheme more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what the value is of the rebate payments made by industry under the Pharmaceutical Price Regulation Scheme to date; and what proportion of that rebate has been reinvested in (i) healthcare services and (ii) medicines expenditure. more like this
tabling member constituency Cambridge more like this
tabling member printed
Dr Julian Huppert more like this
uin 210640 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-20more like thismore than 2014-10-20
answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014 and £76 million in respect of the second quarter. The Department will publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first two quarters PPRS payments were published in June and September 2014 respectively and can be found on the Government’s website at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</a></p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p> more like this
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-20T16:15:30.8911788Zmore like thismore than 2014-10-20T16:15:30.8911788Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
3931
label Biography information for Dr Julian Huppert more like this
93573
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Cancer Drugs Fund: Liverpool more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what proportion of the cancer drugs fund has been spent in Liverpool since its inception. more like this
tabling member constituency Liverpool, Walton more like this
tabling member printed
Steve Rotheram more like this
uin 210689 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-20more like thismore than 2014-10-20
answer text <p>Prior to April 2013, information on the Cancer Drugs Fund was administered through clinical panels based in each strategic health authority (SHA) and data on spend through the Fund in each city was not collected. Information on spend by the North West SHA and in England in 2010-11, 2011-12 and 2012-13 is shown in the following table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Amount Spent (£000)</p><p>2010-11</p></td><td><p>Amount Spent (£000)<br> 2011-12</p></td><td><p>Amount Spent (£000)<br> 2012-13</p></td></tr><tr><td><p>North West SHA</p></td><td><p>7,400</p></td><td><p>10,015</p></td><td><p>29,272</p></td></tr><tr><td><p>England</p></td><td><p>38,254</p></td><td><p>108,327</p></td><td><p>175,334</p></td></tr></tbody></table><p> </p><p><em>Source</em>: Information provided to the Department by SHAs</p><p> </p><p> </p><p> </p><p>NHS England has had oversight of the Fund since April 2013 and does not collect information at city level. In 2013-14, £63,368,429 was spent through the Fund in the North of England region and total national expenditure in England, net of any central rebates, was £230,539,005. Figures for 2014-15 are not currently available.</p><p> </p>
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-20T16:20:31.8199947Zmore like thismore than 2014-10-20T16:20:31.8199947Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4035
label Biography information for Steve Rotheram more like this
93283
registered interest false more like this
date less than 2014-10-14more like thismore than 2014-10-14
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Anticoagulants more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 12 July 2014 to Question 206057, on anticoagulants, what plans the National Institute for Health and Care Excellence has to update that guidance. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 210583 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-17more like thismore than 2014-10-17
answer text <p>The National Institute for Health and Care Excellence (NICE) regularly reviews the need to update its published guidance in order to take account of the latest available evidence.</p><p> </p><p> </p><p> </p><p>We understand that NICE considered updating its technology appraisal guidance on bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230) in 2012 and decided, following consultation with stakeholders, to incorporate the recommendations into its clinical guideline on myocardial infarction with ST-segment elevation (CG167). The guideline was published in July 2013 and NICE has advised that it will undergo a surveillance review two years after its publication, expected in July 2015.</p><p> </p> more like this
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-17T12:35:32.5646725Zmore like thismore than 2014-10-17T12:35:32.5646725Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4036
label Biography information for Luciana Berger more like this
92979
registered interest false more like this
date less than 2014-10-13more like thismore than 2014-10-13
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Pregnancy: Sodium Valproate more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, when he expects the European Medicines Agency's review of valproate and related substances and their use by pregnant women to report; and if he will make a statement. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 210191 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-16more like thismore than 2014-10-16
answer text <p>The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) completed its review of the risk of neurodevelopmental disorders in children exposed to valproate in the womb. PRAC has recommended strengthening the restrictions on the use of valproate. In particular PRAC has recommended that valproate should not be used to treat epilepsy and bipolar disorder in girls, women who can become pregnant or pregnant women unless other treatments are ineffective or not tolerated and that the need for continued treatment should be reviewed regularly. The PRAC recommendations will now be sent to the Member States’ Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) for a final opinion in November. Healthcare professionals and patients will be informed of the new advice once the CMDh has reached a final opinion.</p><p> </p> more like this
answering member constituency Mid Norfolk remove filter
answering member printed George Freeman more like this
question first answered
less than 2014-10-16T15:19:41.6082119Zmore like thismore than 2014-10-16T15:19:41.6082119Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
4036
label Biography information for Luciana Berger more like this